Trade Names:Pristiq- Tablets, ER 50 mg- Tablets, ER 100 mg
Potentiates serotonin and norepinephrine in the CNS.
Absolute bioavailability after oral administration is about 80%. T max is about 7.5 h. Steady state reached in 4 to 5 days.
Plasma protein binding is about 30%. Vd at steady state following IV administration is 3.4 L/kg, indicating distribution into nonvascular compartment.
Primarily by conjugation (UGT isoforms) and to a lesser extent through oxidative metabolism (CYP3A4).
After oral administration, about 45% is excreted unchanged in the urine within 72 h, approximately 19% excreted as the glucuronide, and less than 5% as the oxidative metabolites. Mean half-life is 11 h.
Elimination is correlated with CrCl. The AUC increases about 42% in patients with mild renal impairment, about 46% in those with moderate renal impairment, about 108% in those with severe renal impairment, and about 116% in ESRD. The mean terminal half-life is prolonged from 11.1 h in control subjects to about 13.5, 15.5, 17.6, and 22.8 h in those with mild, moderate, severe, and ESRD, respectively. Less than 5% of the drug is cleared during standard 4-h hemodialysis.Hepatic Function Impairment
Average AUC is increased by about 31% and 35% in patients with moderate and severe hepatic impairment, respectively. Cl is decreased about 20% and 36% in patients with moderate and severe hepatic impairment, respectively. The mean half-life increased from 10 h in healthy subjects to 13 and 14 h in patients with moderate and severe hepatic impairment, respectively. No dosage adjustment is needed in the starting dose for patients with hepatic impairment.Elderly
There is an increase in the AUC and C max of about 55% and 32%, respectively, in patients older than 75 yr of age compared with patients 18 to 45 yr of age. Patients 65 to 75 yr of age had a 32% increase in AUC but no change in C max compared with patients 18 to 45 yr of age.Gender
There is an increase in the AUC and C max of about 10% and 25%, respectively, in women compared with men; however, no dosage adjustment is needed.Race
Race has no apparent effect on pharmacokinetics.
Treatment of major depressive disorder (MDD).
Concomitant use with MAOIs; hypersensitivity to any component of the product.
PO 50 mg once daily. No benefit has been demonstrated at dosages of more than 50 mg/day.Renal function impairmentAdults
POSevere renal impairment (CrCl less than 30 mL/min) or ESRD
50 mg every other day. Do not give supplemental doses after dialysis.
Store at 59° to 86°F.
Risk of bleeding may be increased.CNS-active agents (eg, alcohol)
Coadminister with caution. Patients should avoid alcohol consumption while taking desvenlafaxine.CYP3A4 inhibitors (eg, ketoconazole)
Desvenlafaxine plasma concentrations may be elevated.Drugs metabolized by CYP2D6 (eg, desipramine)
Plasma concentrations may be elevated by desvenlafaxine.Drugs metabolized by CYP3A4 (eg, midazolam)
Plasma concentrations may be decreased by desvenlafaxine.MAOIs
Serious, even fatal, reactions may occur. Do not use desvenlafaxine with MAOIs or within 14 days of MAOI use. Allow at least 7 days after stopping desvenlafaxine before starting MAOIs.Serotonergic drugs (eg, linezolid, metoclopramide, sibutramine, SNRIs, SSRIs, tramadol, trazodone, triptans)
Risk of life-threatening serotonin syndrome may be increased.St. John's wort
Serotonin syndrome may occur.Tryptophan
Concurrent use is not recommended.Venlafaxine-containing drugs
Desvenlafaxine is the active metabolite of venlafaxine. Do not coadminister drugs containing venlafaxine.
None well documented.
Palpitations (3%); hot flush, increased BP, tachycardia (2%); orthostatic hypotension, syncope (less than 2%); coronary occlusion requiring revascularization, MI, myocardia ischemia (rare).
Headache (29%); dizziness (16%); insomnia (15%); somnolence (12%); fatigue (11%); tremor (9%); decreased libido in men (6%); anxiety (5%); abnormal dreams (4%); feeling jittery, paresthesia (3%); asthenia, disturbance in attention, irritability, nervousness (2%); convulsion, depersonalization, extrapyramidal disorder, hypomania (less than 2%).
Hyperhidrosis (21%); rash (2%).
Mydriasis (6%); blurred vision (4%); dysgeusia, tinnitus (2%); epistaxis (less than 2%).
Nausea (41%); dry mouth (25%); constipation (14%); diarrhea (11%); vomiting (9%).
Erectile dysfunction (11%); anorgasmia (men, 8%; women, 3%); proteinuria (8%); delayed ejaculation (7%); ejaculation disorder (5%); abnormal orgasm in men (3%); ejaculation failure, sexual dysfunction, urinary hesitation (2%).
Hypersensitivity (less than 2%).
Increased total cholesterol (10%); increased fasting triglycerides (6%); increased LDL (2%); abnormal liver function, increased blood prolactin (less than 2%).
Decreased appetite (10%); decreased weight (2%).
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for MDD and other psychiatric disorders. Appropriately monitor and closely observe patients of all ages who are started on antidepressant therapy for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the prescriber. Desvenlafaxine is not approved for use in children.
Closely observe patient for clinical worsening, suicidality, or unusual changes in behavior during initial few months of therapy or when increasing or decreasing the dose. Monitor patients with elevated IOP or acute narrow-angle glaucoma. Consider monitoring serum lipids. Monitor BP regularly.
Category C . Neonates exposed to SNRIs or SSRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Consider potential risks and benefits when treating women during the third trimester.
Excreted in breast milk.
Safety and efficacy not established.
Consider the possibility of reduced renal Cl when determining the dose. Systolic orthostatic hypotension occurs more frequently in patients 65 yr of age and older.
Dosage adjustment is recommended.
Risk of bleeding events, ranging from ecchymosis to life-threatening hemorrhages, may be increased.
Sustained increases in BP may occur. Control preexisting hypertension before starting treatment. Use with caution in patients with CV disease, or cerebrovascular or preexisting hypertension.
When discontinuing treatment, a gradual reduction in dosage rather than abruptly stopping therapy is recommended.
Hyponatremia as a result of SIADH may occur. Elderly patients and patients taking diuretics or who are otherwise volume depleted may be at increased risk.
Because these conditions have been associated with venlafaxine, the parent drug of desvenlafaxine, consider the possibility that these adverse reactions may occur.
Activation of mania/hypomania has been reported. Use with caution in patients with a history of mania or hypomania.
Mydriasis may occur.
A major depressive episode may be the initial presentation of bipolar disorder. Treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Screen patients with depression for risk of bipolar disorder prior to initiating therapy with an antidepressant.
Use with caution in patients with a history of seizure disorder.
Potentially life-threatening serotonin syndrome or NMS-like reactions, including mental status changes, may occur.
Dose-related elevations in fasting serum total cholesterol, LDL cholesterol, and triglycerides may occur. Use with caution in patients with lipid metabolism disorders.
Agitation, constipation, diarrhea, dizziness, dry mouth, headache, nausea, paresthesia, tachycardia, vomiting.
Copyright © 2009 Wolters Kluwer Health.